Incyte Pays $1.25B for Vega and Its Bleeding Disorder Drug

Incyte is acquiring Vega Therapeutics in a deal valued at $1.25 billion, bringing in a late-stage drug for von Willebrand disease, an inherited bleeding disorder, MedCity News reports. The candidate offers a novel mechanism of action and a dosing advantage over therapies currently on the market, which is what makes it a potential standout in hematology.

The timing matters. Incyte's top product, the blood cancer drug Jakafi, faces looming patent expiration that threatens a major revenue cliff. Buying late-stage assets is a common way for biopharma companies to backfill pipelines before key drugs lose exclusivity, and Vega gives Incyte a differentiated entry in a space with limited options.

For patients with von Willebrand disease, an improved dosing profile could ease treatment burden if the drug clears late-stage trials and wins approval. For Incyte, the acquisition is a bet that diversification beyond oncology can offset the financial pressure ahead, according to MedCity News.